Alerts will be sent to your verified email
Verify Email
STAR
|
Strides Pharma Scien
|
Marksans Pharma
|
FDC
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
230.0 . | 25.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
215.0 . | 13.0 . | n/a |
|
R&D as a % of Total Sales
|
1.84 % | 2.0 % | 2.22 % |
|
Financials
|
|||
|
5 yr Average ROE
|
23.7 % | 17.57 % | 12.9 % |
|
5yr average Equity Multiplier
|
2.62 | 1.33 | 1.57 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.9 | 0.55 |
|
5yr Avg Net Profit Margin
|
12.9 % | 14.56 % | 15.2 % |
|
Price to Book
|
3.0 | 3.06 | 3.29 |
|
P/E
|
21.1 | 21.57 | 27.9 |
|
5yr Avg Cash Conversion Cycle
|
-51.45 Days | 71.65 Days | -13.89 Days |
|
Inventory Days
|
69.05 Days | 89.77 Days | 61.89 Days |
|
Days Receivable
|
60.35 Days | 65.99 Days | 18.98 Days |
|
Days Payable
|
225.58 Days | 88.81 Days | 89.17 Days |
|
5yr Average Interest Coverage Ratio
|
0.72 | 38.03 | 90.41 |
|
5yr Avg ROCE
|
10.5 % | 21.95 % | 13.8 % |
|
5yr Avg Operating Profit Margin
|
12.17 % | 20.32 % | 17.7 % |
|
5 yr average Debt to Equity
|
1.01 | 0.02 | 0.0 |
|
5yr CAGR Net Profit
|
68.01 % | 10.03 % | -2.41 % |
|
5yr Average Return on Assets
|
10.97 % | 13.19 % | 8.22 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
28.3 % | 43.87 % | 69.66 % |
|
Share Pledged by Promoters
|
50.1 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.07 % | -4.38 % | 0.16 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-0.99 % | 2.6 % | 1.1 % |
|
Strides Pharma Scien
|
Marksans Pharma
|
FDC
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
Customer Segment
|
-
|
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|